Catalyst Pharmaceuticals Inc - Asset Resilience Ratio
Catalyst Pharmaceuticals Inc (CPRX) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2022)
This chart shows how Catalyst Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check Catalyst Pharmaceuticals Inc (CPRX) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Catalyst Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Catalyst Pharmaceuticals Inc (CPRX) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Catalyst Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Catalyst Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Catalyst Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Catalyst Pharmaceuticals Inc (2011–2022)
The table below shows the annual Asset Resilience Ratio data for Catalyst Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $0.00 | $375.63 Million | -- |
| 2021-12-31 | 8.34% | $19.82 Million | $237.79 Million | +3.12pp |
| 2020-12-31 | 5.22% | $10.04 Million | $192.35 Million | +0.76pp |
| 2019-12-31 | 4.46% | $5.01 Million | $112.38 Million | -56.62pp |
| 2018-12-31 | 61.08% | $36.92 Million | $60.45 Million | +30.02pp |
| 2017-12-31 | 31.05% | $26.52 Million | $85.39 Million | -32.51pp |
| 2016-12-31 | 63.57% | $26.51 Million | $41.71 Million | +13.39pp |
| 2015-12-31 | 50.18% | $30.16 Million | $60.10 Million | -18.55pp |
| 2014-12-31 | 68.73% | $30.18 Million | $43.91 Million | -16.00pp |
| 2013-12-31 | 84.73% | $21.49 Million | $25.37 Million | +1.30pp |
| 2012-12-31 | 83.43% | $14.01 Million | $16.79 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $6.25 Million | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more